Literature DB >> 17287272

An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Josh D Nelson1, Florence M Brunel, Richard Jensen, Emma T Crooks, Rosa M F Cardoso, Meng Wang, Ann Hessell, Ian A Wilson, James M Binley, Philip E Dawson, Dennis R Burton, Michael B Zwick.   

Abstract

The membrane-proximal external region (MPER) of human immunodeficiency virus type 1 (HIV-1) gp41 bears the epitopes of two broadly neutralizing antibodies (Abs), 2F5 and 4E10, making it a target for vaccine design. A third Ab, Fab Z13, had previously been mapped to an epitope that overlaps those of 2F5 and 4E10 but only weakly neutralizes a limited set of primary isolates. Here, libraries of Fab Z13 variants displayed on phage were engineered and affinity selected against an MPER peptide and recombinant gp41. A high-affinity variant, designated Z13e1, was isolated and found to be approximately 100-fold improved over the parental Fab not only in binding affinity for the MPER antigens but also in neutralization potency against sensitive HIV-1. Alanine scanning of MPER residues 664 to 680 revealed that N671 and D674 are crucial for peptide recognition as well as for the neutralization of HIV-1 by Z13e1. Ab competition studies and truncation of MPER peptides indicate that Z13e1 binds with high affinity to an epitope between and overlapping with those of 2F5 and 4E10, with the minimal peptide epitope WASLWNWFDITN. Still, Z13e1 remained about an order of magnitude less potent than 4E10 against several isolates of pseudotyped HIV-1. The sum of our molecular analyses with Z13e1 suggests that the segment on the MPER of gp41 between the 2F5 and 4E10 epitopes is exposed on the functional envelope trimer but that access to the specific Z13e1 epitope within this segment is limited. Thus, the ability of MPER-bearing immunogens to elicit potent HIV-1-neutralizing Abs may depend in part on recapitulating the particular constraints that the functional envelope trimer imposes on the segment of the MPER to which Z13e1 binds.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287272      PMCID: PMC1866125          DOI: 10.1128/JVI.02588-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.

Authors:  R Schier; A McCall; G P Adams; K W Marshall; H Merritt; M Yim; R S Crawford; L M Weiner; C Marks; J D Marks
Journal:  J Mol Biol       Date:  1996-11-08       Impact factor: 5.469

2.  Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Authors:  Barton F Haynes; Judith Fleming; E William St Clair; Herman Katinger; Gabriela Stiegler; Renate Kunert; James Robinson; Richard M Scearce; Kelly Plonk; Herman F Staats; Thomas L Ortel; Hua-Xin Liao; S Munir Alam
Journal:  Science       Date:  2005-04-28       Impact factor: 47.728

3.  Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.

Authors:  Xinzhen Yang; Svetla Kurteva; Sandra Lee; Joseph Sodroski
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

Authors:  T R Fouts; J M Binley; A Trkola; J E Robinson; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein.

Authors:  P L Earl; C C Broder; R W Doms; B Moss
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

6.  Preparation and characterization of human HIV type 1 neutralizing reference sera.

Authors:  L K Vujcic; G V Quinnan
Journal:  AIDS Res Hum Retroviruses       Date:  1995-07       Impact factor: 2.205

7.  Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.

Authors:  J P Moore; Y Cao; J Leu; L Qin; B Korber; D D Ho
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.

Authors:  L G Kostrikis; Y Cao; H Ngai; J P Moore; D D Ho
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding.

Authors:  J M Binley; H J Ditzel; C F Barbas; N Sullivan; J Sodroski; P W Parren; D R Burton
Journal:  AIDS Res Hum Retroviruses       Date:  1996-07-01       Impact factor: 2.205

View more
  102 in total

1.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

2.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers.

Authors:  Konstantin Virnik; Yisheng Ni; Ira Berkower
Journal:  Vaccine       Date:  2012-07-06       Impact factor: 3.641

4.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

5.  Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization.

Authors:  Mikyung Kim; Zhen-Yu J Sun; Kasper D Rand; Xiaomeng Shi; Likai Song; Yuxing Cheng; Amr F Fahmy; Shreoshi Majumdar; Gilad Ofek; Yongping Yang; Peter D Kwong; Jia-Huai Wang; John R Engen; Gerhard Wagner; Ellis L Reinherz
Journal:  Nat Struct Mol Biol       Date:  2011-10-16       Impact factor: 15.369

6.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

7.  Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.

Authors:  Mikyung Kim; Likai Song; James Moon; Zhen-Yu J Sun; Anna Bershteyn; Melissa Hanson; Derek Cain; Selasie Goka; Garnett Kelsoe; Gerhard Wagner; Darrell Irvine; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

8.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1.

Authors:  Johannes S Gach; Paul G Furtmüller; Heribert Quendler; Paul Messner; Ralf Wagner; Hermann Katinger; Renate Kunert
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.